The Patent Finder

Melinta Therapeutics, Inc.

12 patents currently held · Updated Nov 17, 2026
44 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded as renamed to Melinta Subsidiary Corp. (2017)

Previously recorded as Rib-X Pharmaceuticals, Inc. (to 2013)

8
Ending by 2030
Sep 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for High Purity Oritavancin and Method of Producing Same (US 10,328,118) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 1 fee due Jun 29, 2027
    The maintenance fee for Method of Inhibiting Clostridium Difficile by Administration of Oritavancin (US 9,220,749) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,629,100Method of Inhibiting Clostridium Difficile by Administration of Oritavancin
In force
 · High confidence
In forceHigh confidence
US 9,220,749Method of Inhibiting Clostridium Difficile by Administration of Oritavancin
In force
 · High confidence
In forceHigh confidence
US 10,201,587Methods of Inhibiting and Treating Biofilms Using Glycopeptide Antibiotics
In force
 · High confidence
In forceHigh confidence
US 8,420,592Methods of Treatment Using Single Doses of Oritavancin
In force
 · High confidence
In forceHigh confidence
US 12,514,899Methods of Treatment Using Single Doses of Oritavancin
In force
 · High confidence
In forceHigh confidence
US 9,682,061Methods of Treating Bacterial Infections Using Oritavancin
In force
 · High confidence
In forceHigh confidence
US 10,947,237Antimicrobial Compounds And Methods Of Making And Using The Same
In force
 · High confidence
In forceHigh confidence
US 11,098,047Antimicrobials and Methods of Making and Using Same
In force
 · High confidence
In forceHigh confidence
US 9,775,878Methods for Treating Bacterial Infections Using Oritavancin and Polymyxins
In force
 · High confidence
In forceHigh confidence
US 9,649,352High Purity Oritavancin and Method of Producing Same
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 44 patents in force now held by others · 18 lapsed for an unpaid fee · 18 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 15 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited